Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2026-02-03 @ 2:04 AM
Study NCT ID:
NCT05483933
Status:
COMPLETED
Last Update Posted:
2025-12-23
First Post:
2022-07-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Sponsor:
Shattuck Labs, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Platinum-resistant Ovarian Cancer | View |
| None | Fallopian Tube Cancer | View |
| None | Epithelial Ovarian Cancer | View |
| None | Ovarian Cancer | View |
| None | Platinum-Resistant Fallopian Tube Carcinoma | View |
| None | Platinum-Resistant Primary Peritoneal Carcinoma | View |
| None | Primary Peritoneal Carcinoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Platinum-resistant | View |
| None | Ovarian | View |
| None | Peritoneal | View |
| None | High grade serous EOC | View |
| None | primary peritoneal cancer | View |
| None | Fallopian | View |
| None | Combination | View |
| None | Mirvetuximab Soravtansine | View |
| None | SL-172154 | View |
| None | SIRPĪ±-Fc-CD40L | View |
| None | Pegylated Liposomal Doxorubicin | View |